About Event
Novel Targeting Moiety & Payload Conjugate Summit Europe - What's It About?
This is the definitive event to explore groundbreaking advancements in conjugate design. With a focus on innovative peptide-drug, bispecific, fragment-drug, radio, degrader, and oligonucleotide conjugates, you'll gain valuable insights into the latest technologies and strategies.
Join key decision-makers from Europe's leading biotechs, discover new ways to enhance tumor targeting and overcome delivery challenges, and learn how to secure crucial funding.Â
Join European biotech and pharma professionals working on novel conjugate drugs and ADCs, eager to explore new formats and innovative payloads. This summit attracts leaders seeking cutting-edge discussions on innovative conjugate design, delivery strategies, and therapeutic advancements.Â
Discover A28 Therapeutics' hormone-lytic peptide conjugation and Valink Technologies' rapid iteration and screening of optimized candidates.Â
Explore novel bispecific conjugate drugs from Shenzhen Enduring Biotech and OBI Pharma, reducing off-target toxicity and overcoming resistance.Â
Learn from Sapreme Technologies and CyGenica on enhancing endosomal escape or bypassing endosomes for efficient oligonucleotide delivery.Â
Discuss with European biotechs and Medixci on how to present proof of concept, PK, and toxicity data to persuade investors to fund next-generation conjugate projects.Â
Dive into ProteinQure's peptide drug conjugates and Sutura Therapeutic's stabilized peptide technology for improved cellular internalization.
Discover groundbreaking degrader and radio payloads from Coherent Biopharma and Coretag, offering new therapeutic possibilities.Â
Who Will You Meet?
